Follow The Filings

LXEO Lexeo Therapeutics Inc.

Health Care, filed as LEXEO THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.3%
  • $1.8M

Who owns this now

Largest portfolio weights among holders, up to 0.3% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel 0.33%

Who owns LXEO

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.33% Hold 377,059 $1.8M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by LXEO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All LXEO insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $313K sold by 1 insider under 10b5-1 plans
  1. Richard Nolan Townsend CEO
    Planned sale
    $313K 55,000 shares at $5.69 14% of stake
    Traded Apr 6 Filed Apr 7
    ↗

Also filed in the last 12 months, not counted as buying or selling: 16 sales to cover taxes and 13 stock grants.

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 2.01,3.02,9.01 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
8-K 5.02 Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$66.39M -$98.33M -$99.96M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $124.29M $126.12M $188.39M
Total non-current assets * $15.51M $20.82M $80.3M
Total assets $139.81M $146.94M $268.69M
Total current liabilities $17.24M $22.85M $16.81M
Total non-current liabilities * $9.03M $7.25M $5.21M
Total equity $113.54M $116.84M $246.67M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$59.5M -$81.15M -$98.56M
Cash from investing -$0.165M -$94.08M -$90.25M
Cash from financing $103.79M $88.78M $216.8M
Net change in cash $44.13M -$86.45M $27.98M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.